Bortezomib, Thalidomide and Dexamethasone (VTD) Is Superior to Bortezomib, Cyclophosphamide and Dexamethasone (VCD) Prior to Autologous Stem Cell Transplantation for Patients with De Novo Multiple Myeloma. Results of the Prospective IFM 2013-04 Trial

Affiliation auteurs!!!! Error affiliation !!!!
TitreBortezomib, Thalidomide and Dexamethasone (VTD) Is Superior to Bortezomib, Cyclophosphamide and Dexamethasone (VCD) Prior to Autologous Stem Cell Transplantation for Patients with De Novo Multiple Myeloma. Results of the Prospective IFM 2013-04 Trial
Type de publicationJournal Article
Year of Publication2015
AuteursMoreau P, Hulin C, Macro M, Caillot D, Chaieteix C, Roussel M, Garderet L, Royer B, Brechgnac S, Tiab M, Puyade M, Escoffre M, Stoppa A-M, Facon T, Pegourie B, Chaoui D, Jaccard A, Slama B, Marit G, Laribi K, Godmer P, Luycx O, Eisenmann JClaude, Allangha O, Claisner S, Dib M, Araujo C, Fontan J, Belhadj K, Wetterwald M, Dorvaux V, Fermand J-P, Rodon P, Kolb B, Lenain P, Planche L, Biron L, Caillon H, Avet-Loiseau H, Dejoie T, Attal M
JournalBLOOD
Volume126
Date PublishedDEC 3
Type of ArticleMeeting Abstract
ISSN0006-4971